800-Patient study aims to tailor sarcoma treatment
NCT ID NCT07432932
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is collecting tissue samples and medical data from 800 high-risk sarcoma patients to develop personalized treatment approaches. Researchers will analyze genetic and protein profiles to better predict which patients benefit from chemotherapy before surgery. The goal is to create a tool that helps doctors choose the most effective treatment for each individual.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could lead to personalized chemotherapy plans for high-risk sarcoma patients, potentially improving survival and reducing recurrence.
- What could go wrong
- This is an observational study, not a treatment trial. It may not directly benefit participants, and the findings might not translate into clinical practice for years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANGIOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The Royal Marsden Hospital
RECRUITINGLondon, SW3 6JJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor-Injected drug combo outlast standard care in advanced sarcoma?
- Can engineered immune cells tackle childhood sarcoma?
- Can a Patient's own immune cells be engineered to fight a rare sarcoma?
- Can a Patient's own immune cells fight advanced sarcoma?
- Could a massive tissue bank unlock sarcoma's secrets?
- Smartwatch exercise plan aims to rebuild fitness in young cancer survivors